The latest insights on ADCs for HR-Positive, HER2-low metastatic breast cancer – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X:

”Paolo Tarantino will discuss the latest insights on ADCs for HR-Positive, HER2-low metastatic breast cancer in the ESMO24 Industry Satellite Symposium – Redefining Care for HR+ MBC.

Date: Monday, September 16th.
Time: 19:20 CEST (13:20 pm EST).
Location: Valencia Auditorium, – Hall 5.”

Source: Dana-Farber’s Breast Oncology Center/X

Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.

As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.

Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.